Multiple Myeloma: Inside the Issue of Cereblon E3 Ligase Modulators
About this episode
Dr Natalie S Callander from the University of Wisconsin Carbone Cancer Center in Madison and Dr Paul G Richardson from Dana-Farber Cancer Institute in Boston, Massachusetts, discuss the potential role of CELMoDs in the management of multiple myeloma, supporting clinical data and ongoing investigations.
CME information and select publications here.
Get every episode summarized
Each time Hematologic Oncology Update publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from Hematologic Oncology Update
CD19 x CD3 BiTEs for Acute Lymphoblastic Leukemia — An Interview with Dr Bijal S...
Hematologic Oncology Update
Chronic Lymphocytic Leukemia — An Interview with Prof Constantine Tam on Key Pre...
Hematologic Oncology Update
Immune Thrombocytopenia — Microlearning Activity 2 with Dr Hanny Al-Samkari: ASH...
Hematologic Oncology Update
Immune Thrombocytopenia — Microlearning Activity 1 with Dr Hanny Al-Samkari: ASH...
Hematologic Oncology Update